News
-
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma Reports on the First Nine Months of Financial Year 2026
Heidelberg Pharma AG reports on first nine months of financial year 2026: progress in clinical trials & cost savings. Financial figures up 79%. Strategic partnerships with Huadong Medicine. Focus on ADC development -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma Presented New Clinical Data for Lead ATAC Candidate Pamlectabart Tismanitin at IMS Annual Meeting 2026
Heidelberg Pharma presents new clinical data for lead ATAC candidate Pamlectabart Tismanitin at IMS Annual Meeting 2026, establishing Recommended Phase 2 Dose at 175 µg/kg and demonstrating favorable safety and efficacy in multiple myeloma patients -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma to Present New Clinical Data on Lead ATAC Candidate Pamlectabart Tismanitin at International Myeloma Society Annual Meeting 2026
Heidelberg Pharma to present new clinical data on lead ATAC candidate Pamlectabart Tismanitin at International Myeloma Society Annual Meeting 2026 -
